Revolo Biotherapeutics Announces Positive Data from

Revolo Biotherapeutics Announces Positive Data from

News Highlights

NEW ORLEANS and LONDON, May 04, 2021 (News) — Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission in patients with autoimmune (‘1805 a protein drug) and allergic disease (‘1104 a peptide drug), announced today positive data from a multiple ascending dose (MAD) Phase 1 clinical trial evaluating the safety and tolerability of ‘1104, a first-in-class peptide for the treatment of allergic disease. The data demonstrated that ‘1104 was safe and well-tolerated at the two doses evaluated (4 and 8 mg) without serious adverse events.

“These data, together with the previous positive safety data seen in a Phase 1 clinical trial of ‘1104 in 94 healthy volunteers and people with mild asthma, support the thesis that ‘1104 is a safe and tolerable treatment option for people with allergic disease,” said Jeff Myers M.D. Ph.D., Chief Medical Officer of Revolo Bio. “In totality, the findings support continued advancement and further evaluation of ‘1104 in our upcoming Phase 2 clinical trials.”

Jonathan Rigby, Chief Executive Officer of Revolo Bio, added, “Despite decades of research, people with allergic diseases are still in need of treatments that provide long-term disease remission and avoid immunosuppression. In multiple preclinical studies, ‘1104 effectively reduced the number of key cells involved in allergic inflammation.  The encouraging safety data support our plan to evaluate ‘1104 in two upcoming Phase 2 clinical trials in eosinophilic esophagitis and allergen sensitivity.”

The Phase 1 randomized, double-blind, placebo-controlled clinical trial (NCT04748536) was designed to evaluate the safety and tolerability of multiple doses of ‘1104 in healthy volunteers. The study enrolled 18 subjects in two cohorts. The first cohort (n=8) received 4 mg of ‘1104 (n=6) intravenously or placebo (n=2) once daily for five days. The second cohort (n=10) received 8 mg of ‘1104 (n=8) intravenously or placebo (n=2) once daily for seven days.

About ‘1104‘1104 is a first-in-class peptide derived from a natural immune-regulatory protein, mTB Chaperonin 60.1 that is involved in resetting the immune system. Revolo Bio is advancing ‘1104 through two Phase 2 trials: one in patients with eosinophilic esophagitis (EoE) and one is patients with allergen sensitivity, while exploring its potential for other allergic diseases.

About Revolo Biotherapeutics Revolo Biotherapeutics is developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic disease, without the immune system suppression seen with current therapies. Its two drug candidates, ‘1805 and ‘1104, a protein and a peptide respectively, reset the immune system by preventing the chronic pro-inflammatory immune response that results in autoimmune or allergic disease. ‘1805 is a modified analogue of a key protein in immune function and is entering clinical development for its second Phase 2 trial in moderate-to-severe rheumatoid arthritis and a Phase 2 clinical trial in non-infectious uveitis. ‘1104 is a peptide derived from a natural immune-regulatory protein and is entering Phase 2 clinical development for patients with eosinophilic esophagitis (EoE) and allergic disease. The disease-agnostic mechanism of action of Revolo Biotherapeutic’s assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases.

For further information, please visit www.revolobio.com.

Company ContactMarylyn Rigby, VP Investor Relations & Marketing marylyn.rigby@revolobio.com

Media Contact Monica Rouco Molina, Ph.D.LifeSci Communications+1-929-469-3850mroucomolina@lifescicomms.com

  • Check the latest Health news updates and information.
  • Please share this news Revolo Biotherapeutics Announces Positive Data from with your friends and family to support us your one share helps us a lot.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
Florida resident convicted of trademark counterfeiting and money laundering conspiracies involving online sale and distribution of unapproved drugs obtained abroad |  USAO-WDPA

Florida resident convicted of trademark counterfeiting and money laundering conspiracies involving online sale and distribution of unapproved drugs obtained abroad | USAO-WDPA

Source www.justice.gov Kulakevich and Belani previously pleaded guilty for their roles in the etizolam conspiracies—among other offenses as to Belani—and ...
How about 'Monkey Business' in Clinton?

Auto insurance provider Metromile to adopt Bitcoin, will pay crypto claims

Metromile’s goal is to earn customers by saving them money through a pay-by-mile model with fully automated claims, in most cases. “Metromile gives drivers ...
American stores to take food prepared by GiGi’s Genesis Health Bar

American stores to take food prepared by GiGi’s Genesis Health Bar

Source To purchase the grab-and-go items, customers are encouraged to visit any Fort Wayne All-American store (located at 513 E Dupont Rd,, 6520 Lima Rd. and ...
CONDITIONS FOR PURCHASES OF CORPORATE BONDS

CONDITIONS FOR PURCHASES OF CORPORATE BONDS

News Highlights ...
Browsers see increased business for Mother’s Day |  Mid-Missouri News

Browsers see increased business for Mother’s Day | Mid-Missouri News

“A lot of it is mailing cards and small gifts,” Roberts said.  He said business has increased some this year due to the pandemic, but he said Mother’s Day week ...
Texas political adviser accused of money-changing scheme, campaign contributions to marijuana licenses

Texas political adviser accused of money-changing scheme, campaign contributions to marijuana licenses

Texas passed a law in 2019 opening the door for local farmers to grow hemp as a crop. The state Department of Agriculture, tasked with setting rules for the ...
2 Your health: tips for making the transition back to the classroom

2 Your health: tips for making the transition back to the classroom

She said it can also be helpful to talk to your child’s teacher. They, too, are readjusting to life back in the classroom and can offer some guidance. “My big ...
City creates fund for Fed financial aid

City creates fund for Fed financial aid

Mayor Jim Lienhoop said earlier this year that the city wants to be “thoughtful and cautious” about its use of funds and would begin the decision-making ...
At Scott Twp., Brewery raises gift and money for brain cancer research |  News

At Scott Twp., Brewery raises gift and money for brain cancer research | News

Paul Caviston, Caviston-Ashmar’s father, approached the Scott Twp. brewery about two months ago with the idea to join in, Lastauskas said. Ryan Caviston said ...
Heartland has been revealed as a surprise free-to-play console and PC game

Heartland has been revealed as a surprise free-to-play console and PC game

At this point, we know that more content is being planned for The Division 2 in the future. We know there’s a Netflix movie coming. But today brought the ...
Show next
Compsmag - Latest News from tech, business and health
Logo